natgillin/translations-raw huggingface dataset:
Thus according to an embodiment of the invention, the lozenges have a final water content of approximately 5-20% by weight. 
Tako, prema varijanti izuma, tablete imaju krajnju količinu vode u postocima od približno 5-20% po masi.
Best results, however, are obtained in water containing food products, particularly water-continuous food products. 
Međutim, najbolji rezultati se postižu u prehrambenim proizvodima koji sadržavaju vodu, naročito vodenim prehrambenim proizvodima.
The extrudate is pelletized. 
Ekstrudat se peletizira.
A compound of Formula I: wherein Z is H, that is 2-fluoro-11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine, or a pharmaceutically acceptable salt thereof. 
S I naznačen time da Z je H, koji je 2-fluoro-11-(piperazin-1-il)dibenzo[b,f][1,4]tiazepin, ili njegova farmaceutski prihvatljiva sol.
The method of embodiment 116, wherein the cancer is chronic myelogenous leukemia. The method of embodiment 116, wherein the cancer is gastrointestinal stromal tumor. The method of embodiment 116, wherein the cancer is selected from the group consisting of chronic myelomonocytic leukemia, hypereosinophilic syndrome, renal cell carcinoma, hepatocellular carcinoma, Philadelphia chromosome positive acute lymphoblastic leukemia, non-small cell lung cancer, pancreatic cancer, breast cancer, a solid tumor, head and neck cancer and mantle cell lymphoma. 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 14 ili farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačeni time što su namijenjeni upotrebi u liječenju raka, gdje se po mogućnosti rak bira iz skupine koju čine kronična mijelogena leukemija, kronična mijelomonocitna leukemija, hipereozinofilni sindrom, karcinom bubrežnih stanica, hepatocelularni karcinom, akutna limfoblastična leukemija pozitivna na filadelfijski kromosom, rak velikih stanica pluća, rak gušterače, rak dojke, čvrsti tumor, tumor gastrointestinalne strome, rak glave i vrata i limfom stanica plašta.
The radiographic apparatus according to claim 1, wherein the radiation emitting device and the radiation detecting device are movable parallel relative to each other at an equal speed relative to the patient. 
Uređaj za dijagnostičku radiologiju prema zahtjevu 1, gdje se aparat za emitiranje zračenja (2) i ravni detektor (3) međusobno mogu paralelno pomicati jednakom brzinom u odnosu na bolesnika (M).
The dental post according to at least one of the claims 1 to 2, characterized in that X-ray absorbing material is embedded in said post. 
Zubni potporanj u skladu s najmanje jednim od patentnih zahtjeva 1 do 11, naznačen time što je materijal koji apsorbira rendgenske zrake usađen u navedeni potporanj.
Such bypass channels 49 allows the base part 5 and the base unit 3 to be used as described above for the embodiment shown in figs. 2a-c . 
Takovi spojni kanali 49 omogućuju da se osnovni dio 5 i osnovna jedinica 3 prema ovoj izvedbi izuma upotrijebe kao što je gore opisano za izvedbu prikazanu na slikama 2a-c.
and R54 are each, independently, —H, methyl, ethyl, or isopropyl; or R53 and R54 taken together with the carbon atoms to which they are attached form a phenyl, cyclohexenyl, or cyclooctenyl ring; and 
Rs3 i Rs su svaki nezavisno -H, metil, etil ili izopropil; ili R53 1 Rsa uzeti zajedno sa ugljikovim atomima za koje su vezani čine fenil, cikloheksenil ili ciklooktenil prsten; i
It is particularly preferred for the matrix of lozenges according to the invention to comprise: 
Posebno je poželjno da matriks tablete prema izumu sadrži;
An antibody that specifically binds to avB5 integrin, wherein the antibody is a humanized form of the antibody produced by the hybridoma deposited as ATCC Deposit No. 
PTA-5817. Protutijelo koje se specifično veže na avfB5 integrin, naznačeno time, da je protutijelo u humaniziranom obliku od protutijela proizvedenog od hybridoma deponiranog kao ATCC Depozit Br.
At this point the potential energy in the wireline converts to kinetic energy which drives the jar mandrel 13 explosively upwardly. 
U ovom trenutku se potencijalna energija u žicanoj vezi transformira u kinetičku energiju, koja onda eksplozivno pogoni vreteno 13 udaraca prema gore.
A composition according to claim 23 wherein the antipsychotic agent is selected from the group consisting of aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and sertindole. 
. Pripravak prema zahtjevu 25, gdje se antipsihotični agens bira 1z skupine koja se sastoji od aripiprazola, klozapina, olanzapina, risperidona, kvetiapina 1 sertindola.
(a)selecting at least two amino acid positions within the VH region for mutation; and 
(A) odabiranje najmanje tri aminokiselinske pozicije unutar Vr-područja za mutaciju; 1
A nucleic acid molecule according to claim 6, wherein the nucleic acid molecule comprises the heavy chain variable region nucleic acid SEQ ID NO: 32 and the light chain variable region nucleic acid SEQ ID NO: 2. 
Molekula nukleinske kiseline u skladu s patentnim zahtjevom 6, pri čemu molekula nukleinske kiseline obuhvaća nukleinsku kiselinu varijabilne regije teškog lanca SEQ ID NO:32 i nukleinsku kiselinu varijabilne regije lakog lanca SEQ ID NO:2.
A microencapsulated bacterial consortium, according to claim 1, wherein the proteolytic enzyme of bacterial origin and the proteolytic enzyme of fungal origin are selected from enzymes commonly used for baking. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su proteolitički enzim bakterijskog porijekla 1 proteolitički enzim gljivičnog porijekla odabrani od enzima koji se obično koriste za pečenje.
The water vehicle of claim 4, wherein the frame comprises a mounting bracket arranged to support an auxiliary device mounted thereon. 
Plovilo iz zahtjeva 4, naznačeno time da okvir (114) čine nosači za montiranje raspoređeni da podupiru pomoćnu napravu montiranu na njega.
an aldehyde comprising at least one of the following: a monoaldehyde (Diagram 1), a dialdehyde (Diagram 2) and a cyclic aldehyde (Diagram 3) in a 0.001% to 25% m/v concentration: 
(a) aldehid koji obuhvaća barem jedno od sljedećeg: monoaldehid (Dijagram 1), dialdehid (Dijagram 2) i ciklički aldehid (Dijagram 3) koncentracije 0.001% do 25% m/v: R-CHO
the bacterial strain is viable; and/or 
(d) bakterijska vrsta je održiva; i/ili
The process of claim 1, wherein said first solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, Dimethylsulfoxide, diphenyl ether, Dimethylacetamide, and mixtures of 2 pr more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno prvo otapalo se bira iz skupine koju čino ksilen, V-metilpirolidinon, dimetil-sulfoksid, difenil-eter i dimetilacetamid, te smjese 2 ili više njih.
homogenization of the ground substance; 
- < homogenizacija mljevene supstance;
In most cases, these techniques employ physicochemical methods of influence on a stratum (well bottom zone) and on transport systems that transport oil from the stratum to the surface. 
U većini slučajeva ti postupci koriste fizikalno-kemijske metode s utjecajem na naslage (zonu dna izvora) te na prijenosne sustave koji prenose naftu iz naslaga na površinu.
The dispensing closure according to claim 1 wherein the piston (4) is hollow. 
Zatvarač sustava razdjeljivanja prema zahtjevu 1, naznačen time, da klip (4) je šupalj.
Another object of the invention is a method for producing at least one glycosylated polypeptide, comprising transforming microalgae or transformed microalgae as described here above with a nucleotide sequence operably linked to a promoter that drives expression in said microalgae, wherein said nucleotide sequence encodes a glycosylated polypeptide that is expressed in the transformed microalgae. 
(i) kultiviranja transformirane mikroalge Phaeodactylum tricornutum, koja sadrži nukleotidnu sekvencu operativno vezanu za pokretač koji pokreće ekspresiju u navedenoj mikroalgi, gdje navedena nukleotidna sekvenca kodira glikozilirani polipeptid koji je eksprimiran u transformiranoj mikroalgi tako da se postigne ekspresija navedenog najmanje jednog glikoziliranog polipeptida, i,
Thus, the disclosure provides an antibody that binds to an epitope recognised by an antibody having the variable heavy chain sequence recited in SEQ ID NO: 89, and the variable light chain sequence recited in SEQ ID NO: 103. 
(e) varijabilno područje slabog lanca od sekvence SEQ ID NO: 89, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 103;
In some embodiments, the disorder involving hyperproliferation of skin cells is hyperkeratosis. In other embodiments, the condition is an autoimmune disease, such as rheumatoid arthritis, lupus, Crohn's disease, or psoriasis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je autoimuna bolest odabrana od reumatoidnog artritisa, lupusa, Crohnove bolesti, te psorijaze.
The audio decoding method of example 8, wherein the mixing coefficients are determined such that the two channels of the output signal receive contributions of equal magnitude from the decorrelated signal, the contributions from the decorrelated signal to the respective channel of the output signal having opposite signs. 
Postupak audio dekodiranja u skladu s patentnim zahtjevom 5, naznačen time što K = 3, te što se formiranje izlaznog signala sastoji u projiciranju iz četiri kanala u tri kanala.
The synthesis may also be carried out in one pot as a multicomponent reaction. 
Sintezu se također može provesti u jednoj posudi, poput višekomponentne reakcije.
The method of claim 7 wherein the KGF comprises the amino acid sequence of SEQ ID NO: 2. 
Postupak prema patentnom zahtjevu 12 naznačen time što je KGF izabran iz grupe koju čine SEQ ID NO: 2, SEQ
The method of treatment according to claim 5, wherein the clinical condition is selected from the group consisting of benign gastric ulcer, gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer, duodenal ulcer associated with Helicobacter pylori, and prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complication who require continued NSAID treatment and combination therapy with antibiotics in the eradication of Helicobacter pylori. 
Uporaba prema zahtjevu 8, naznačena time, da je kliničko stanje odabrano iz skupine koju čine: benigni gastrični ulkus, bolest gastrofagealnog refluksa, Zollinger-Ellison-sindrom, duodenalni ulkus, duodenalni ulkus povezan s bakterijom Helicobacter pylori, profilaksa za gastrični ili duodenalni ulkus povezan s NSAID kod pacijenata s povećanim rizikom za gastroduodenalne komplikacije koje zahtijevaju sustavno NSAID liječenje i kombinacijsku terapiju s antibioticima za eradikaciju bakterije Heliobacter pylori.
The base station apparatus according to claim 1 wherein said allocating unit is configured to allocate Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, to the second mobile station in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
A propulsion unit nozzle (1) according to claim 1, wherein the hydrodynamic elements are of a casted material. 
Pogonska jedinica mlaznice (1) u skladu s patentnim zahtjevom 1, naznačena time što su hidrodinamički elementi (12) od lijevanog materijala.
wherein the signal includes a frequency notch band which is inserted into the signal across the signal frame and the PLP includes Layer 2, L2, signaling data carrying Program Specific Information/Service Information, PSI/SI, data. The method of claim 5, wherein the L2 signaling data includes a Network Information Table, NIT, having an identifier of a physical layer pipe (PLP_id) and an identifier of a C2 system (C2_system_id) corresponding to the transport stream, TS, and wherein a C2 delivery system descriptor includes the identifier of the PLP and the identifier of the C2 system in a TS loop of the NIT maps transport streams to PLPs in data slices of the C2 systems. 
sredstva (1803) za dobivanje NIT uključujući identifikator PLP-a (PLP_id) i identifikator C2 sustava (C2_system_id) iz sloj 2, L2 informacije okvira signala, i dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru C2 sustava uključenog u NIT; i sredstva (1804) za dobivanje prijenosnog toka prema kojem je PLP mapiran, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a i identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava.
The set of PDCCHs may be monitored in the unit of the aggregation level in the search space. 
Postupak prema zahtjevu 1, naznačen time da su skupovi PDCCH-ova nadzirani u jedinici na razini prikupljanja u prostoru pretraživanja.
Then the solution was slowly allowed to cool and crystallization started. 
Nakon toga otopina je ostavljena da se polako hladi i započela je kristalizacija.
In one embodiment of the present invention the compound is of formula (I) herein below: wherein: 
PATENTNI ZAHTJEVI 1. Spoj formule (I), kao što je prikazano niže:
Figure 15 shows the bioactivity of IL-2 microaggregates, before and after dilution with serum, and a comparison with monomeric IL-2. 
Slika 15 pokazuje bioaktivnost mikroagregata IL-2, prije i nakon razrjeđenja sa serumom i usporedbu s monomernim IL-2.
a chimeric protein comprising a Transcription Activator-Like Effector Nuclease (TALEN). 
(b) Transkripcijsku efektornu nukleazu poput aktivatora (TALEN).
A method according to any of the preceding claims wherein a subject is considered to have a highly elevated probability of developing preeclampsia if the HbF-ratio exceeds 0.0020, 0.0025 0.0060, or 0.01 and the A1M level exceeds 21µg/ml, 23µg/ml, 25µg/ml, 30µg/ml, 35µg/ml, or 40µg/ml. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se smatra da subjekt ima jako povećanu vjerojatnost za razvoj preeklampsije ako omjer HbF-a prelazi 0,0020, 0,0025 0,0060 ili 0,01 te razina AIM-a prelazi 21 ug/ml, 23 ug/ml, 25 ug/ml, 30 ug/ml, 35 ug/ml ili 40 ug/ml.
VLP according to at least one of the above claims, wherein the VLP is composed of VP1 proteins of JC virus. 
Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu po sastavu virusu slične čestice (VLP) čine proteini virusnog proteina 1 (VP1) od JC virusa,
An immunoconjugate comprising an antibody according to any one of claims 1 to 4 conjugated or linked to at least one growth inhibitory agent. 
Imunokonjugat naznačen time da sadrži protutijelo prema bilo kojem od zahtjeva 1 do 19 konjugirano ili vezano na najmanje jedno sredstvo za inhibiciju rasta.
After 35 minutes, the diethyl ether layer from Step 71a (1.8 mL) is added. 
Nakon 35 minuta doda se sloj u dietil eteru iz stupnja 7la (1,8 ml).
In the present invention it was found that a the polyvinylidene emulsions used had the best results if the emulsions resulted in dried films having gas transmissions in the following ranges, for oxygen the range was 1 to 100 cm3-um/(m2-day-bar) at 25° C. and 85% relative humidity with the most preferred range being 10-80 cm3-um/(m2-day-bar) at 25° V and 85% relative humidity, for water vapor the range was 1-50 g-um/(m2-day) at 38° C. and 90% relative humidity, with 10-30 g-um/(m2-day) at 38° C. and 90% relative humidity being preferred. 
U predstavljenom izumu je nađeno da su korištene poliviniliden emulzije imale najbolje rezultate ako emulzije prijeđu u osušeni film koji posjeduje sljedeće opsege vrijednosti za prijenos plina, za kisik taj opseg je 1 do 100 cm3-pun/(m2-dan-bar) na 25%C i 85% relativne vlažnosti, sa najpoželjnijim opsegom 10-80 cm3-um/(m2-dan-bar) na 25%C i 85% relativne vlažnosti, za vodenu paru taj opseg je 1-50 g-um/ (m2-dan) na 38*C i 90% relativne vlažnosti, a poželjno 10-30 g-pum/(m2-dan) na 38?C i 90% relativne vlažnosti.
Finally, the base (10) is in this case provided with a number of glass supporting areas (10 ′) equal to the number of inclined conduits (12) provided in the dispenser (7). A wine aerating or oxygenating device, comprising: 
Uređaj za pretakanje vina prema patentnom zahtjevu 10, u čemu, spomenuto samonivelirajuće sredstvo postolja (10) sadrži stopice s podesivom visinom, pretežno sadrže vijke s vertikalnom osi (11) spregnutom u navojnim otvorima dobivenim u ovoj bazi (10).
calculate a weighted average of the RSRP values of the plurality of MRs for each neighbor cell of the plurality of neighbor cells, wherein the weighted average is calculated based the RSRP values and the incremental weightages assigned to the RSRP values, and 
RSREP,, = čem, gdje w; označuje ponderiranje inkrementa, MR; označuje RSRP vrijednosti primljene za više i=0 Vi susjednih ćelija, k označuje periodne intervale vremena primanja RSRP vrijednosti, a RSRP,, je ponderirani prosjek RSRP vrijednosti.
1328-53-6) and blue 29 (typically ultramarine blue). 
1328-53-6) i plavi (tipično ultramarin plavi).
A compound according to claim 27, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 form, together with the N atom to which they are bound, a saturated heterocyclic group of formula (a). 
Spoj u skladu s patentnim zahtjevom 12, naznačen time, da R2 1 R3 tvore, zajedno s N atomom za kojeg su vezani, zasićenu heterocikličku skupinu od formule (a). 15.
The rotary machine as claimed in claim 10, wherein the machine comprises a connecting link rod (60) coupled to the at least one pair of mechanisms (1) arranged in series, the connecting link rod (60) being stationary in a horizontal direction, and movable in a vertical direction during the movement of the mechanisms (1). 
Rotacijski stroj prema zahtjevu 10, naznačen time da se stroj sastoji od klipnjače (60) povezane s mehanizmima (1) poredanim u seriju, pri čemu klipnjača (60) kad je nepomična slijedi vodoravni smjer, a kad je pomična slijedi okomiti smjer kretanja mehanizama (1).
A packaging according to claim 1, wherein the first and second sides comprise guiding members for guiding the two sides in relation to each other upon closing the packaging. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što prve i druge strane sadržavaju članove za vođenje koji vode dvije strane, jednu u odnosu na drugu, prilikom zatvaranja pakiranja.
In a preferred embodiment of the invention, the forward and reverse primers used in the amplification of the nucleic acid sample may contain within a longer sequence or comprise solely of the following sequences or a fragment thereof: Forward primer: 5′ GAGCTAACCGGAGAGGGAGA 3′ 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što početnice koje se upotrebljava za amplificiranje uzorka nukleinske kiseline mogu u sebi sadržavati dulji slijed ili se sastojati samo od sljedećih sljedova ili njihovih fragmenata: početnice prema naprijed: 5'-GAGCTAACCGGAGAGGGAGA-5' početnice prema natrag: 5'-CGCATACCGACTTTCGTCAA-5".
The humanized antibody according to claim 1 having a variable heavy chain and a variable light chain comprising the amino acid sequences of SEQ ID NO:53 and SEQ ID NO:52, respectively. 
Humanizirano anti-CD40 antitijelo koje ima varijabilan teški lanac i varijabilan laki lanac koji sadrže aminokiselinske sekvence sa SEQ ID NO:53 i SEQ ID NO:52, redom, gdje antitijelo sadrži humanu imunoglobulinski Fc regiju i gdje antitijelo je IgG1 antitijelo.
Cardiac allograft vasculopathy is an unusually accelerated and diffuse form of coronary atherosclerosis that limits the long-term success of cardiac transplantation. 
Kardijalna vaskulopatija alografta je neobično ubrzan i raširen oblik koronarne ateroskleroze koji ograničava dugotrajan uspjeh kardijalne transplantacije.
and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which Het1 is morpholino, Aa1 is 1,1′-biphen-4-yl or 1,1′-biphen-3-yl, 
R611 1R612, zajedno s i uključivši atom dušika na kojeg su vezani, tvore heterociklički prsten Hetl, gdje Het1 je morfolino, Aal je 1,1'-bifen-4-il ili 1,1'-bifen-3-il,
The reaction can be carried out by heating the reactants in the neat amino compound or dissolved in an inert solvent under standard conditions, e.g. in an alcohol such as methanol, at elevated temperature, such as between 40 to 60° C., or at reflux. 
Reakcija može biti provedena grijanjem reaktanata u čistom amino spoju ili otapanjem u inertnom otapalu pod standardnim uvjetima, u alkoholu poput metanola, kod povišene temperature, na primjer između 40 i 60%C, ili pod refluksom.
A light source as claimed in claim 1, wherein the antenna is a rod or wire of conductive metal extending within a re-entrant in the plasma crucible and the connection is an integral extension of the antenna rod or wire. 
Svjetlosni izvor u skladu s bilo kojim patentnim zahtjevom od 1 do 10, naznačen time, da je antena šipka ili žica provodljivog metala koja se proteže u udubljenju u plazmenoj retorti, a priključak je cjeloviti nastavak antenske šipke ili žice.
mixture of polypeptides of the invention in a 
Datum objave europske prijave patenta:
reacting a compound of Formula (V) with an amine of Formula (VI) in the presence of a base in a solvent to form a compound of Formula (Ia) and optionally subjecting the compound of Formula (Ia) to hydrogenation or 
reakciju spoja s Formulom (V) s aminom s Formulom (VI) u prisutnosti baze u otapalu da nastane spoj s Formulom (Ia) i proizvoljno podvrgavanje spoja s Formulom (Ia) hidrogeniranju ili
A method according to any one of claims 1 to 3, wherein the composition is administered by means selected from intramuscular, intraperitoneal, intravenous, subcutaneous, rectal, nasal, oral, intragastric and pulmonary. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je sastav za davanje subjektu intramuskularno, intraperitonealno, intravenski, subkutano, rektalno, nazalno, oralno, intragastrično i plućno.
Utility of compounds of the invention as screening agents 
Datum objave europskog patenta:
The frustoconical- or truncated pyramid-shaped support structure formed by several precast concrete panels according claim 1, characterized in that the panels (1) are pre-tensioned or post-tensioned internally, i.e., inside the concrete section, before the placement thereof, not requiring any additional tensioning cable on-site. 
Nosiva struktura u obliku krnjeg stošca - ili u obliku krnje piramide formirana od nekoliko predgotovljenih betonskih panela prema prethodnim zahtjevima, naznačena time da su paneli (1) unaprijed zategnuti ili interno naknadno-zategnuti, tj. unutar betonskog dijela, prije njegovog stavljanja, što na licu mjesta ne zahtijeva nikakve dodatne kabel za zatezanje.
determining whether the compound increases a blood GLP-1 level in the mammal; wherein the ability of the test compound to increase a blood GLP-1 level in the mammal is indicative of the test compound being a GLP-1 secretagogue or a compound useful for treating or preventing a condition ameliorated by increasing a blood GLP-1 level. 
(d) određivanje nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj u prisutnosti kojeg je formirano manje navedenog kompleksa u koraku (c); pri čemu je sposobnost test spoja da poveća nivo GLP-1 u krvi nadalje indikativna da je test spoj GLP-1 sekretogog.
A method according to claim 5, wherein multiple genes coding for polypeptides of a biochemical pathway are recombined and assembled. 
Metoda u skladu s patentnim zahtjevom 5 ili 6, pri čemu su višestruki geni koji kodiraju za polipeptide biokemijskog puta rekombinirani i sklopljeni.
A product or composition of claim 8, wherein the inhibitor of thyroid hormone synthesis is methimazol or a prodrug thereof, such as carbimazole. 
Sastav iz patentnog zahtjeva 1, pri čemu je inhibitor sinteze hormona štitnjače metimazol ili karbimazol.
The combined organic layers are washed with water (1x20 mL) followed by brine solution (1x25 mL) and dried over Na2SO4. 
Pomiješane organske slojeve ispere se vodom (1 x 20 ml) 1 slanom otopinom (1 x 25 ml), te osuši preko Na»SOx.